Cytosorbents (NASDAQ:CTSO) Earns "Buy" Rating from D. Boral Capital

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price target on the medical research company's stock.

A number of other research firms also recently weighed in on CTSO. StockNews.com assumed coverage on Cytosorbents in a research note on Saturday, February 22nd. They issued a "hold" rating on the stock. HC Wainwright reissued a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $4.67.

Cytosorbents Stock Down 0.9 %

Shares of CTSO traded down $0.01 during mid-day trading on Tuesday, reaching $1.06. The company's stock had a trading volume of 81,334 shares, compared to its average volume of 330,319. The company has a market cap of $57.96 million, a price-to-earnings ratio of -2.94 and a beta of 0.61. The business has a fifty day moving average of $1.03 and a 200 day moving average of $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61.

Remove Ads

Institutional Investors Weigh In On Cytosorbents

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new position in shares of Cytosorbents during the fourth quarter worth $30,000. Renaissance Technologies LLC raised its holdings in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after buying an additional 8,400 shares during the last quarter. Northern Trust Corp boosted its position in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Geode Capital Management LLC grew its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.